304 related articles for article (PubMed ID: 33800465)
1. Insulin Resistance across the Spectrum of Nonalcoholic Fatty Liver Disease.
Armandi A; Rosso C; Caviglia GP; Bugianesi E
Metabolites; 2021 Mar; 11(3):. PubMed ID: 33800465
[TBL] [Abstract][Full Text] [Related]
2. Molecular Mechanisms of Nonalcoholic Fatty Liver Disease (NAFLD)/Nonalcoholic Steatohepatitis (NASH).
Ota T
Adv Exp Med Biol; 2021; 1261():223-229. PubMed ID: 33783745
[TBL] [Abstract][Full Text] [Related]
3. Nonalcoholic steatohepatitis versus steatosis: adipose tissue insulin resistance and dysfunctional response to fat ingestion predict liver injury and altered glucose and lipoprotein metabolism.
Musso G; Cassader M; De Michieli F; Rosina F; Orlandi F; Gambino R
Hepatology; 2012 Sep; 56(3):933-42. PubMed ID: 22684858
[TBL] [Abstract][Full Text] [Related]
4. IMPACT OF TYPE 2 DIABETES ON NONALCOHOLIC STEATOHEPATITIS AND ADVANCED FIBROSIS IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE.
Bian H; Zhu X; Xia M; Yan H; Chang X; Hu X; Pan B; Guo W; Li X; Gao X
Endocr Pract; 2020 Apr; 26(4):444-453. PubMed ID: 31968197
[No Abstract] [Full Text] [Related]
5. Crosstalk between adipose tissue insulin resistance and liver macrophages in non-alcoholic fatty liver disease.
Rosso C; Kazankov K; Younes R; Esmaili S; Marietti M; Sacco M; Carli F; Gaggini M; Salomone F; Møller HJ; Abate ML; Vilstrup H; Gastaldelli A; George J; Grønbæk H; Bugianesi E
J Hepatol; 2019 Nov; 71(5):1012-1021. PubMed ID: 31301321
[TBL] [Abstract][Full Text] [Related]
6. Cardiovascular risk, lipidemic phenotype and steatosis. A comparative analysis of cirrhotic and non-cirrhotic liver disease due to varying etiology.
Loria P; Marchesini G; Nascimbeni F; Ballestri S; Maurantonio M; Carubbi F; Ratziu V; Lonardo A
Atherosclerosis; 2014 Jan; 232(1):99-109. PubMed ID: 24401223
[TBL] [Abstract][Full Text] [Related]
7. The Role of Insulin Resistance and Diabetes in Nonalcoholic Fatty Liver Disease.
Fujii H; Kawada N; Japan Study Group Of Nafld Jsg-Nafld
Int J Mol Sci; 2020 May; 21(11):. PubMed ID: 32485838
[TBL] [Abstract][Full Text] [Related]
8. Modulation of Insulin Resistance in Nonalcoholic Fatty Liver Disease.
Khan RS; Bril F; Cusi K; Newsome PN
Hepatology; 2019 Aug; 70(2):711-724. PubMed ID: 30556145
[TBL] [Abstract][Full Text] [Related]
9. Prevalence of Nonalcoholic Steatohepatitis-Associated Cirrhosis in the United States: An Analysis of National Health and Nutrition Examination Survey Data.
Kabbany MN; Conjeevaram Selvakumar PK; Watt K; Lopez R; Akras Z; Zein N; Carey W; Alkhouri N
Am J Gastroenterol; 2017 Apr; 112(4):581-587. PubMed ID: 28195177
[TBL] [Abstract][Full Text] [Related]
10. Treatment of Nonalcoholic Fatty Liver Disease.
Liangpunsakul S; Chalasani N
Curr Treat Options Gastroenterol; 2003 Dec; 6(6):455-463. PubMed ID: 14585234
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of circulating zonulin as a potential marker in the pathogenesis of nonalcoholic fatty liver disease.
Hendy OM; Elsabaawy MM; Aref MM; Khalaf FM; Oda AMA; El Shazly HM
APMIS; 2017 Jul; 125(7):607-613. PubMed ID: 28430371
[TBL] [Abstract][Full Text] [Related]
12. Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus.
Dharmalingam M; Yamasandhi PG
Indian J Endocrinol Metab; 2018; 22(3):421-428. PubMed ID: 30090738
[TBL] [Abstract][Full Text] [Related]
13. Nonalcoholic fatty liver disease: from steatosis to cirrhosis.
Farrell GC; Larter CZ
Hepatology; 2006 Feb; 43(2 Suppl 1):S99-S112. PubMed ID: 16447287
[TBL] [Abstract][Full Text] [Related]
14. Pathophysiology of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis.
Manne V; Handa P; Kowdley KV
Clin Liver Dis; 2018 Feb; 22(1):23-37. PubMed ID: 29128059
[TBL] [Abstract][Full Text] [Related]
15. Hepatic transcriptome signatures in patients with varying degrees of nonalcoholic fatty liver disease compared with healthy normal-weight individuals.
Suppli MP; Rigbolt KTG; Veidal SS; Heebøll S; Eriksen PL; Demant M; Bagger JI; Nielsen JC; Oró D; Thrane SW; Lund A; Strandberg C; Kønig MJ; Vilsbøll T; Vrang N; Thomsen KL; Grønbæk H; Jelsing J; Hansen HH; Knop FK
Am J Physiol Gastrointest Liver Physiol; 2019 Apr; 316(4):G462-G472. PubMed ID: 30653341
[TBL] [Abstract][Full Text] [Related]
16. Insulin resistance in nonalcoholic fatty liver disease.
Bugianesi E; Moscatiello S; Ciaravella MF; Marchesini G
Curr Pharm Des; 2010 Jun; 16(17):1941-51. PubMed ID: 20370677
[TBL] [Abstract][Full Text] [Related]
17. The role of liver fat and insulin resistance as determinants of plasma aminotransferase elevation in nonalcoholic fatty liver disease.
Maximos M; Bril F; Portillo Sanchez P; Lomonaco R; Orsak B; Biernacki D; Suman A; Weber M; Cusi K
Hepatology; 2015 Jan; 61(1):153-60. PubMed ID: 25145475
[TBL] [Abstract][Full Text] [Related]
18. Nonalcoholic fatty liver disease: pathogenesis and the role of antioxidants.
Mehta K; Van Thiel DH; Shah N; Mobarhan S
Nutr Rev; 2002 Sep; 60(9):289-93. PubMed ID: 12296456
[TBL] [Abstract][Full Text] [Related]
19. Irisin in patients with nonalcoholic fatty liver disease.
Polyzos SA; Kountouras J; Anastasilakis AD; Geladari EV; Mantzoros CS
Metabolism; 2014 Feb; 63(2):207-17. PubMed ID: 24140091
[TBL] [Abstract][Full Text] [Related]
20. Fatty liver: role of inflammation and fatty acid nutrition.
Byrne CD
Prostaglandins Leukot Essent Fatty Acids; 2010; 82(4-6):265-71. PubMed ID: 20189787
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
